Skip to main content

Table 4 Effect of the tested drugs on the liver and kidney functions in alloxan-induced diabetic rats after 4 weeks

From: Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

Biochemicals
Group ALP(IU/L) AST(IU/L) Urea (mmol/L) Creatinine (mmol/L)
Normal control group 60.85 ± 8.77 25.04 ± 4.96 43.38 ± 4.77 0.46 ± 0.07
Diabetic control group 89.05 ± 10.44* 45.86 ± 7.57* 75.81 ± 18.85* 1.89 ± 0.19*
Diabetic group treated with Bromocriptine 68.83 ± 7.27# 34.18 ± 5.78# 60.41 ± 6.22# 1.04 ± 0.26#
Diabetic group treated with Cabergoline 73.27 ± 7.93# 21.37 ± 10.05# 52.09 ± 2.23# 0.79 ± 0.11#
Diabetic group treated with Sarpogrelate 82.16 ± 23.83 41.47 ± 10.02 69.41 ± 7.65 1.68 ± 0.25
Diabetic group treated with Bromocriptine + sarpogrelate 64.8 ± 7.21# 31.03 ± 6.44# 44.4 ± 8.23# 1.26 ± 0.25#
Diabetic group treated with cabergoline + sarpogrelate 73.44 ± 6.68# 33.79 ± 11.18# 51.16 ± 10.43# 1.33 ± 0.21#
  1. Values shown are means ± SEM; n = 6 rats per group. * P < 0.05, significantly different from the normal control group; # P < 0.05, significantly different from the diabetic control group